Loading stock data…
Nuvectis Pharma (NVCT)
$19.31-0.84 (-4.17%)
Market ClosedLast close Jul 24
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvectis Pharma, Inc. in the Healthcare sector is trading at $19.31 with a market capitalization of $305M. Wall Street consensus targets $31.00 (4 analysts), implying a +60.5% move over the next 12 months. The stock is currently 34% below its 52-week high of $29.27, remaining 99.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +60.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.26M↑ | -$7.62M↑ | -$7.79M↓ | -$6.59M↓ | -$5.57M |
| Net Income | -$6.05M↑ | -$7.31M↑ | -$7.46M↓ | -$6.33M↓ | -$5.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$304.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-191.00%
Volume
Today's trading volume
245,631
Recent News
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)
Secondary offering priced well below previous closeNuvectis Pharma (NASDAQ:NVCT) shares dropped 25% in premarket trading on Tuesday after the clinical-stage biopharmaceutical company priced a $100 million public offering at $20. 00 per share, substantially below Monday’s closing price of $28.
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Haisco and Nuvectis sign licensing deal for two drugs
Haisco will receive $40m upfront and may earn up to $1.4bn in additional milestone payments.